Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Jun 2021
Historique:
revised: 10 03 2021
received: 16 10 2020
accepted: 17 03 2021
pubmed: 21 3 2021
medline: 16 6 2021
entrez: 20 3 2021
Statut: ppublish

Résumé

According to TCGA database, mutations in PPP6C (encoding phosphatase PP6) are found in c. 10% of tumors from melanoma patients, in which they coexist with BRAF and NRAS mutations. To assess PP6 function in melanoma carcinogenesis, we generated mice in which we could specifically induce BRAF(V600E) expression and delete Ppp6c in melanocytes. In these mice, melanoma susceptibility following UVB irradiation exhibited the following pattern: Ppp6c semi-deficient (heterozygous) > Ppp6c wild-type > Ppp6c-deficient (homozygous) tumor types. Next-generation sequencing of Ppp6c heterozygous and wild-type melanoma tumors revealed that all harbored Trp53 mutations. However, Ppp6c heterozygous tumors showed a higher Signature 1 (mitotic/mitotic clock) mutation index compared with Ppp6c wild-type tumors, suggesting increased cell division. Analysis of cell lines derived from either Ppp6c heterozygous or wild-type melanoma tissues showed that both formed tumors in nude mice, but Ppp6c heterozygous tumors grew faster compared with those from the wild-type line. Ppp6c knockdown via siRNA in the Ppp6c heterozygous line promoted the accumulation of genomic damage and enhanced apoptosis relative to siRNA controls. We conclude that in the presence of BRAF(V600E) expression and UV-induced Trp53 mutation, Ppp6c haploinsufficiency promotes tumorigenesis.

Identifiants

pubmed: 33743547
doi: 10.1111/cas.14895
pmc: PMC8177767
doi:

Substances chimiques

Trp53 protein, mouse 0
Tumor Suppressor Protein p53 0
Braf protein, mouse EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
Phosphoprotein Phosphatases EC 3.1.3.16
protein phosphatase 6 EC 3.1.3.16

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2233-2244

Subventions

Organisme : JSPS KAKENHI
ID : 19K18757
Organisme : JSPS KAKENHI
ID : 18K16043
Organisme : JSPS KAKENHI
ID : 17K07187

Informations de copyright

© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Cancer Sci. 2021 Jun;112(6):2233-2244
pubmed: 33743547
FEBS J. 2013 Jan;280(2):324-45
pubmed: 22519956
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Cancers (Basel). 2019 Jul 27;11(8):
pubmed: 31357599
Cancer Lett. 2015 Sep 1;365(2):223-8
pubmed: 26054846
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Nat Genet. 2012 Sep;44(9):1006-14
pubmed: 22842228
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Biochem Soc Trans. 2017 Jun 15;45(3):693-701
pubmed: 28620030
Methods Mol Biol. 2011;731:141-50
pubmed: 21516405
Mod Pathol. 2006 Feb;19 Suppl 2:S41-70
pubmed: 16446716
J Cutan Pathol. 2012 Jan;39(1):33-9
pubmed: 22050235
J Cell Biol. 2010 Dec 27;191(7):1315-32
pubmed: 21187329
Mech Dev. 2016 Feb;139:1-9
pubmed: 26868000
J Cell Sci. 2013 Aug 1;126(Pt 15):3429-40
pubmed: 23729733
FEBS J. 2011 Jun;278(12):2044-54
pubmed: 21481188
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):74-82
pubmed: 30036567
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
PLoS One. 2009;4(2):e4395
pubmed: 19198648
Genes Dev. 2007 Feb 15;21(4):379-84
pubmed: 17299132
Oncogene. 2015 Aug 27;34(35):4647-55
pubmed: 25486434
Cell. 2009 Oct 30;139(3):468-84
pubmed: 19879837
J Biol Chem. 2006 Aug 11;281(32):22624-34
pubmed: 16769727
Cell Cycle. 2011 May 1;10(9):1411-9
pubmed: 21451261
Am J Surg Pathol. 2001 Jan;25(1):58-64
pubmed: 11145252
Cell. 2012 Jul 20;150(2):251-63
pubmed: 22817889
J Biol Chem. 2006 Dec 29;281(52):39891-6
pubmed: 17079228
Cancer Sci. 2018 Jul;109(7):2178-2187
pubmed: 29758119
Am J Surg Pathol. 2019 Apr;43(4):480-488
pubmed: 30475255
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D590-8
pubmed: 16381938
J Biol Chem. 2012 Mar 16;287(12):9230-9
pubmed: 22298787
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Genome Biol. 2016 Feb 22;17:31
pubmed: 26899170
J Cancer Res Ther. 2018;14(Supplement):S132-S137
pubmed: 29578163

Auteurs

Kosuke Kanazawa (K)

Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Division of Surgery, Miyagi Cancer Center, Miyagi, Japan.
Division of Cancer Molecular Biology, Tohoku University School of Medicine, Miyagi, Japan.

Kazuhiro Kishimoto (K)

Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Division of Cancer Molecular Biology, Tohoku University School of Medicine, Miyagi, Japan.
Department of Head and Neck Surgery, Kanazawa Medical University, Ishikawa, Japan.

Miyuki Nomura (M)

Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.

Koreyuki Kurosawa (K)

Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Department of Plastic and Reconstructive Surgery, Tohoku University School of Medicine, Miyagi, Japan.

Hiroyuki Kato (H)

Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.

Yui Inoue (Y)

Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.

Koh Miura (K)

Division of Surgery, Miyagi Cancer Center, Miyagi, Japan.

Katsuya Fukui (K)

Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Division of Cancer Molecular Biology, Tohoku University School of Medicine, Miyagi, Japan.

Yoji Yamashita (Y)

Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.

Ikuro Sato (I)

Division of Pathology, Miyagi Cancer Center, Miyagi, Japan.

Hiroyuki Tsuji (H)

Department of Head and Neck Surgery, Kanazawa Medical University, Ishikawa, Japan.

Toshio Watanabe (T)

Department of Biological Science, Graduate School of Humanities and Sciences Nara Women's University, Nara, Japan.

Takuji Tanaka (T)

Research Center of Diagnostic Pathology, Gifu Municipal Hospital, Gifu, Japan.

Jun Yasuda (J)

Division of Cancer Molecular Biology, Tohoku University School of Medicine, Miyagi, Japan.
Cancer Genome Center, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Tohoku Medical Megabank Organization, Tohoku University, Miyagi, Japan.

Nobuhiro Tanuma (N)

Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Division of Cancer Molecular Biology, Tohoku University School of Medicine, Miyagi, Japan.

Hiroshi Shima (H)

Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Miyagi, Japan.
Division of Cancer Molecular Biology, Tohoku University School of Medicine, Miyagi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH